ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The Strategy delivered double-digit returns in the quarter but trailed the soaring benchmark. Underperformance was driven by underexposure to top AI infrastructure stocks as well as weaknesses in healthcare and consumer discretionary sectors. The market leadership expanded beyond mega-cap technology, indicating potential opportunities from a broader cyclical recovery and AI adoption. In addition, you can check the Fund’s top five holdings to determine its best picks for 2026.
In its Q2 2026 investor letter, ClearBridge SMID Cap Growth Strategy highlighted TG Therapeutics, Inc. (NASDAQ:TGTX) as a leading contributor. TG Therapeutics, Inc. (NASDAQ:TGTX) is a leading commercial-stage biopharmaceutical company focusing on the development of novel treatments for B-cell mediated diseases. On July 10, 2026, TG Therapeutics, Inc. (NASDAQ:TGTX) closed at $57.12 per share, reflecting a market capitalization of $8.74 billion. TG Therapeutics, Inc. (NASDAQ:TGTX) posted a one-month return of 13.56%, while its shares gained 46.76% over the past 52 weeks.
ClearBridge SMID Cap Growth Strategy stated the following regarding TG Therapeutics, Inc. (NASDAQ:TGTX) in its Q2 2026 investor update:
“Biotechnology, however, was a bright spot, with multiple holdings delivering strong performance. TG Therapeutics, Inc. (NASDAQ:TGTX), a commercial-stage biopharmaceutical company focused on therapies for multiple sclerosis, contributed following greater than anticipated growth for its key drug, Briumvi, as well as positive clinical data for a subcutaneous version of the therapy that could expand its addressable market.”
TG Therapeutics, Inc. (NASDAQ:TGTX) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 42 hedge fund portfolios held TG Therapeutics, Inc. (NASDAQ:TGTX) at the end of the first quarter, up from 40 in the previous quarter. While we acknowledge the risk and potential of TG Therapeutics, Inc. (NASDAQ:TGTX) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TG Therapeutics, Inc. (NASDAQ:TGTX) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered TG Therapeutics, Inc. (NASDAQ:TGTX) and shared a bullish thesis on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
